CETP
Cholesteryl ester transfer protein
Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that facilitates the transfer of cholesteryl esters from the atheroprotective high density lipoprotein (HDL) to the proatherogenic low density lipoprotein cholesterol (LDL) and very low density lipoprotein cholesterol (VLDL) leading to lower levels of HDL but raising the levels of proatherogenic LDL and VLDL. CETP inhibitors are a class of drugs that targets the CETP enzyme to significantly increase serum HDL-C and decrease LDL-C levels. Inhibition of CETP is considered a potential approach to treat dyslipidemia.
Alterations of CETP activity levels can be caused by single-base polymorphisms as well as by alternative splicing. Several common variants in CETP have been reported to be associated with variation in plasma lipid levels, CAD risk and/or CETP mass/activity. The rare genetic variants in the CETP gene also contribute to the phenotypic variation of HDL-C in the general population.
All Product Categories
-
CETP 関連製品 (35)
関連製品 (35)
-
抗体 (1)
- 1
- 2
-
20-HC-Me-Pyrrolidine
0 Images製品番号: HY-145001純度: 99.69%20-HC-Me-Pyrrolidine (compound AI-3d) is a potent Aster protein inhibitor with IC50s of 0.11 μM, 0.06 μM, and 0.71 μM for Aster-A, Aster-B, and Aster-C, respectively. 20-HC-Me-Pyrrolidine blocks the ability of Asters to bind and transfer cholesterol. 20-HC-Me-Pyrrolidine also inhibits the movement of low-density lipoprotein (LDL) cholesterol to the endoplasmic reticulum (ER).
-
Torcetrapib
(トルセトラピブ)
0 Images別名: Torcetrapib; CP-529414
-
Evacetrapib
(Evacetrapib)
0 Images別名: LY2484595Evacetrapib is a potent and selective of CETP inhibitor, which inhibits human recombinant CETP protein (IC50 5.5 nM) and CETP activity in human plasma (IC50 36 nM) in vitro.
-
Obicetrapib
0 Images別名: TA-8995; DEZ-001; AMG-899Obicetrapib (TA-8995; DEZ-001) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).
-
Dalcetrapib
(Dalcetrapib)
0 Images別名: JTT-705; RO4607381Dalcetrapib (JTT-705) is an orally active cholesteryl ester transfer protein (CETP) inhibitor with IC50s of 204.6 nM and 6 μM against recombinant human (rh) CETP and human plasma CETP, respectively.
-
UBA6-IN-1
0 ImagesUBA6-IN-1 is a UBA6/UBE1L2 inhibitor (IC50 ≤50 nM) that acts by reducing the level of squalene epoxidase (SQLE). UBA6-IN-1 affects SREBP-dependent lipid metabolism processes and downstream cholesteryl ester transport, and can be used for cancer research.
-
BAY 60-5521
0 Images製品番号: HY-116719CAS 番号: 893409-49-9BAY 60-5521 is an orally active cholesteryl ester transfer protein (CETP) inhibitor with an IC50 of 7 nM. BAY 60-5521 inhibits CETP-mediated transfer of cholesteryl esters from HDL to LDL/VLDL, as well as the transfer of triglycerides from LDL/VLDL to HDL. It dose-dependently increases HDL-C and HDL concentrations, and slightly reduces triglyceride levels. BAY 60-5521 can be used in studies related to dyslipidemia.
-
Obicetrapib potassium
0 Images製品番号: HY-18778BCAS 番号: 866399-90-8別名: TA-8995 potassium; DEZ-001 potassium; AMG-899 potassiumObicetrapib (TA-8995; DEZ-001) potassium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potassium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib potassium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).
-
α-Amylcinnamaldehyde
0 Images別名: 2-Benzylideneheptanal; α-Pentylcinnamaldehydeα-Amylcinnamaldehyde is a ligand for the Niemann-Pick type C2 (NPC2) protein of arthropod moths and may play a key role in the identification of moth volatiles. NPC2 is a key enzyme for cholesterol transport in the body.
-
CP-532623
0 Images製品番号: HY-123039CAS 番号: 261947-38-0CP-532623 is a CETP inhibitor and elevates high-density lipoprotein cholesterolion. CP-532623 is a close structural analogue of Torcetrapib. CP-532623 has highly lipophilic properties.
-
MK-8262
0 Images製品番号: HY-132303CAS 番号: 1432054-03-9MK-8262 is an orally active and potent cholesteryl ester transfer protein (CETP) inhibitor with an IC50 of 53 nM and a log D of 5.3. MK-8262, a bistrifluoromethyl analogue, has the potential for coronary heart disease (CHD) correlated high-density lipoprotein (HDL) and low-density lipoprotein (LDL) research.
-
TAP311
0 Images製品番号: HY-107997CAS 番号: 1149362-88-8TAP311 is a cholesteryl ester transfer protein (CETP) inhibitor with an IC50 of 62 nM.
-
CETP-IN-3
0 Images製品番号: HY-128338CAS 番号: 939391-31-8CETP-IN-3 (Compound 13) is an small molecule inhibitor of the plasma glycoprotein cholesterol ester transfer protein (CETP), elevating HDL-C through inhibition of CETP. CETP-IN-3 for the CETP inhibitory activity in the scintillation proximity (SPA) and whole plasma assay (WPA) with IC50s of 0.002 μM and 0.06 μM, respectively.
-
Rosenonolactone
0 ImagesRosenonolactone shows inhibitory activity against prolyl endopeptidase and thrombin and cholesterol ester transfer protein.
-
3-Pyridinemethanol-d6
0 Images製品番号: HY-W740341CAS 番号: 1189493-62-63-Pyridinemethanol-d6 is the deuterium labeled 3-Pyridinemethanol (HY-B0893). 3-Pyridinemethanol (Nicotinyl alcohol), a pyridine derivative, is a cholesterol-lowering agent.
-
BMS-795311
0 Images製品番号: HY-19614CAS 番号: 939390-99-5BMS-795311 is a potent and orally bioavailable inhibitor of cholesteryl ester transfer protein (CETP), with IC50s of 4 nM in an enzyme-based scintillation proximity assay (SPA) and 0.22 μM in a human whole plasma assay (hWPA), respectively.
-
Tiqueside
0 Images製品番号: HY-106106CAS 番号: 99759-19-0別名: CP‐88,818; β‐Tigogenin cellobiosideTiqueside (CP‐88,818) is an orally active cholesterol absorption inhibitor. Tiqueside inhibits absorption of both dietary cholesterol and endogenous cholesterol excreted into the intestinal lumen via the bile. Tiqueside can be used in the research of hypercholesterolemia.
-
BI-5756
0 Images製品番号: HY-171883CAS 番号: 1332485-18-3BI-5756 is a CETP inhibitor and cannabinoid receptor 1 (CB1) agonist. BI-5756 can significantly increase HDL-C levels and reduce LDL-C levels. BI-5756 can also enhance the function of regulatory T cells while maintaining T cell-mediated anti-tumor activity. BI-5756 can directly inhibit the growth of tumor cells and upregulate the expression of MHC I, MHC II, and CD80 on tumor cells. BI-5756 has a protective effect in graft-versus-host disease models. BI-5756 can be used in research on tumors, graft-versus-host disease, and metabolic diseases.
- 1
- 2
